This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
August 01, 2019
Q2 2019 General Market Overview
July 31, 2019
Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update
July 31, 2019
Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
July 29, 2019
Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress
July 25, 2019
BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report
July 25, 2019
BONESUPPORT HOLDING AB (publ) – Publishes Q2 2019 Interim report
July 24, 2019
GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update
July 23, 2019
MIPS INTERIM REPORT JANUARY – JUNE 2019
July 16, 2019
Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
July 12, 2019
GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule